2026 International Spring Forum
April 15, 2026 | 12:00 PM EST
Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma
Published Date: April 16, 2025

This expert-led session offers oncology professionals a comprehensive overview of MZL subtypes, traditional treatment pathways, and the promising role of targeted oral therapies—specifically BTK inhibitors such as zanubrutinib.
Topics covered include:
- The unique characteristics and prognosis of the three MZL subtypes: MALT lymphoma, nodal MZL, and splenic MZL
- The evolving role of targeted therapies in treating relapsed or refractory MZL
- Clinical data and outcomes from the MAGNOLIA study on zanubrutinib
- Detailed information on dosing strategies, safety profile, and patient management considerations
- Guidance on managing drug interactions, side effects, and special patient populations